ADMA Biologics, Inc.
Here’s whether ADMA Biologics, Inc. (ADMA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 42 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-11.66% over 10 days); weak 1-year return of -60.0%; 3-month momentum negative (-49.6%). Currently 64.4% off its 52-week high. Score: -5/7.
ADMA is trading below its 200-day MA ($14.72) — a key warning sign the longer-term trend is under pressure. An RSI of 42.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -60.0% compares to +24.4% for SPY (trailed the market by 84.4%). The current 64.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.